Le Lézard
Classified in: Ebola virus, Health
Subject: RCL

Advisory - Unauthorized supplements seized from Atomik Nutrition in Châteauguay may pose serious health risks


OTTAWA, Feb. 10, 2017 /CNW/ -

Issue
Health Canada is advising Canadians that it has seized unauthorized health products promoted as workout, weight loss and dietary supplements from Atomik Nutrition at 102-90 Boul. Saint-Jean-Baptiste, Châteauguay, QC (see table below). The products are labelled to contain various drugs, including prescription and controlled drugs, which may pose serious risks to the health of Canadians.

Who is affected

Affected products

Product Name

Manufacturer

Labelled ingredient(s)

Dust Extreme

Blackstone Labs

1,3 DMAA (Dimethylamylamine), Caffeine Anhydrous

Yohimbine HCl

Primaforce

Yohimbine HCl

Insane Cutz

Insane Labz

Rauwolfia Vomitoria Extract (std. min. 90% alpha Yohimbine)

Exo-13 Exothermic Fatburner

Prime Nutrition

1,3-Dimethylamylamine, Caffeine Anhydrous, Yohimbine HCl, Bitter Orange Extract 30%

Amped

Osmo Pharma

Corynanthe Extract (Pausinystalia Yohimbe Bark)

DHEA

Osmo Pharma

Dehydroepiandrosterone (DHEA)

Dymethazine

Osmo Pharma

17ß?hydroxy?2?,17?dimethyl?5??androstan?3?one azine

 

What consumers should do

Background
1,3-Dimethylamylamine (DMAA) is a drug that is not authorized for use in Canada. Side effects include high blood pressure, shortness of breath, chest pain, stroke and psychiatric effects.

Yohimbine (also contained in Rauwolfia extract) is a prescription drug and should be used only under the supervision of a health care professional. The use of drugs containing yohimbine (either as yohimbine hydrochloride or yohimbe bark extract) may result in serious adverse reactions, particularly in people with high blood pressure, or heart, kidney or liver disease. Side effects associated with yohimbine include increased blood pressure and heart rate, anxiety, dizziness, tremors, headache, nausea and sleep disorders. It should not be used by children, or pregnant or nursing women.

Rauwolfia is a prescription drug that can be used to treat high blood pressure (hypertension). It should be used only under the supervision of a health care professional. People with heart conditions or psychiatric disorders should receive close medical supervision when using it because it can make certain conditions, such as depression, worse. Common side effects include tiredness, sleepiness, depression, nasal obstruction and breathlessness. Rauwolfia should not be used by children, or pregnant or nursing women.

Synephrine and caffeine, when combined, may cause serious adverse effects. Side effects include dizziness, tremors, headaches and irregularities in heart rate. Bitter Orange Extract is a source of synephrine.

DHEA is a controlled drug that can cause higher than normal levels of female and male hormones in the body and could increase the risk of prostate, breast, ovarian, and other hormone-sensitive cancers. Potential side effects include serious cardiovascular disease, and changes in fertility and sperm production. DHEA should be avoided by individuals with a history of abnormal heart rhythms, blood clotting disorders, liver disease and those who are pregnant or breast-feeding.

Mebolazine (Dimethazine) is a controlled drug. Potential side effects include serious liver and kidney damage, as well as psychological changes, decreased sperm count and high cholesterol.

What Health Canada is doing
Health Canada seized the products from the retail location. Should additional retailers or distributors be identified, Health Canada will take appropriate action and inform Canadians as necessary.

For more information
Stay connected with Health Canada and receive the latest advisories and product recalls using social media tools.

To learn more about natural health products and other self-care products, visit Canada.ca/selfcare-products.

 

Également disponible en français

 

SOURCE Health Canada


These press releases may also interest you

21 mar 2019
The "Europe Welding Equipment Market-Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering. Welding is one of the critical processes employed in the manufacturing...

21 mar 2019
Inovio Pharmaceuticals, Inc. announced today that its Ebola vaccine, INO-4201, was safe, tolerable, and generated strong T cell and antibody responses. This Phase 1 data was published in The Journal of Infectious Diseases and further supports the...

20 mar 2019
Merck , known as MSD outside the United States and Canada, and NGM Biopharmaceuticals, Inc. (NGM) today announced that Merck has exercised its option to extend the research phase of the companies' broad, strategic collaboration...

20 mar 2019
The shareholders in Sandvik Aktiebolag are convened to the Annual General Meeting to be held on Monday, 29 April 2019 at 3:00 p.m. at the Göransson Arena, Sätragatan 21, Sandviken, Sweden. RIGHT TO PARTICIPATE AND NOTICE Shareholders who wish to...

20 mar 2019
The Oslo Business for Peace Award is given to inspiring business leaders who have put society first. 2019's winners are: Dr Agbor Ashumanyi Ako, medical director of GiftedMom, Alice Laugher, CEO of Committed to...

19 mar 2019
The evolving competitive market has made it essential for the telecommunication industry to rethink traditional ways of doing business in terms of the impact on business models, service portfolios and technical architectures. Digital business support...



News published on and distributed by: